Orleans Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-3,817
Closed -$427K 87
2021
Q4
$427K Sell
3,817
-1,637
-30% -$197K 0.24% 64
2021
Q3
$686K Sell
5,454
-12,456
-70% -$1.6M 0.44% 50
2021
Q2
$2.42M Buy
17,910
+970
+6% +$128K 1.55% 30
2021
Q1
$2.3M Hold
16,940
1.56% 27
2020
Q4
$2.38M Buy
16,940
+1,105
+7% +$142K 1.71% 25
2020
Q3
$1.76M Buy
15,835
+3,650
+30% +$409K 1.35% 33
2020
Q2
$1.36M Buy
+12,185
New +$1.2M 1.11% 37

Other funds holding XBI

Orleans Capital Management's XBI Position: Q1 2022 in Review

Orleans Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 3,817 shares — an estimated $427K sold.

Orleans Capital Management first reported a position in XBI in Q2 2020 and held it in 7 quarters. The position peaked at $2.42M in Q2 2021. 702 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

  • Orleans Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
  • Orleans Capital Management sold 3,817 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $427K.
  • Orleans Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and held it in 7 quarters.
  • Orleans Capital Management's State Street SPDR S&P Biotech ETF position peaked at $2.42M in Q2 2021.
  • 702 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Orleans Capital Management's 13F filing for Q1 2022, filed 13 May 2022.